Page last updated: 2024-08-21

pyrazines and daunorubicin

pyrazines has been researched along with daunorubicin in 16 studies

Research

Studies (16)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (6.25)29.6817
2010's8 (50.00)24.3611
2020's7 (43.75)2.80

Authors

AuthorsStudies
Bousquet-Dubouch, MP; Burlet-Schiltz, O; Gallay, N; Manenti, S; Matondo, M; Monsarrat, B; Payrastre, B; Recher, C; Uttenweiler-Joseph, S1
Lin, MF; Ouyang, GF1
Gong, YP; Yang, X; Zheng, BH; Zhou, RQ1
Chang, H; Gong, YP; Xing, HY; Yang, L; Yang, X; Zheng, BH; Zhou, RQ1
Gong, Y; Shan, Q; Yang, X; Zheng, B; Zhou, R1
Amrein, PC; Attar, EC; Bloomfield, CD; Blum, W; DeAngelo, DJ; Johnson, JL; Kolitz, JE; Larson, RA; Lozanski, G; Marcucci, G; Moser, B; Powell, BL; Stone, RM; Voorhees, P; Wadleigh, M; Wang, ES1
Batár, P; Bedekovics, J; Hevessy, Z; Illés, A; Kiss, A; Márton, A; Pinczés, L; Rejtő, L; Reményi, G; Selmeczi, A; Szász, R; Telek, B; Udvardy, M; Ujfalusi, A; Ujj, Z1
Fu, BB; Li, J; Li, YC; Liao, AJ; Liu, ZG; Wang, HH; Yang, W; Yang, Y; Zhang, R1
Tiong, IS; Wei, AH1
DiNardo, CD; Wei, AH1
Burnett, A; Stone, R1
Andrews, C; Maze, D; Murphy, T; Sibai, H1
Bhatnagar, B; Blachly, JS; Blum, WG; Byrd, JC; Crosswell, HE; Lin, TL; Liu, J; Long, L; Mims, AS; Minden, MD; Munugalavadla, V; Oellerich, T; Orwick, S; Pan, Y; Rao, AV; Serve, H; Walker, AR; Zhang, D1
Thol, F1
Arrigo, G; Audisio, E; Cerrano, M; D'Ardìa, S; Frairia, C; Freilone, R; Giai, V; Secreto, C; Urbino, I1
Allert, C; Bauer, M; Besenbeck, B; Blank, MF; Bruckmann, M; Göllner, S; Heid, D; Janssen, M; Krijgsveld, J; Müller-Tidow, C; Pauli, C; Renders, S; Rohde, C; Trumpp, A; Waclawiczek, A; Wickenhauser, C; Zimmermann, SMN; Zinz, R1

Reviews

4 review(s) available for pyrazines and daunorubicin

ArticleYear
New drugs creating new challenges in acute myeloid leukemia.
    Genes, chromosomes & cancer, 2019, Volume: 58, Issue:12

    Topics: Aminopyridines; Aniline Compounds; Cytarabine; Daunorubicin; fms-Like Tyrosine Kinase 3; Gemtuzumab; Glycine; Humans; Leukemia, Myeloid, Acute; Pyrazines; Pyridines; Staurosporine; Triazines; United States; United States Food and Drug Administration

2019
AML: New Drugs but New Challenges.
    Clinical lymphoma, myeloma & leukemia, 2020, Volume: 20, Issue:6

    Topics: Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cytarabine; Daunorubicin; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Phenylurea Compounds; Pyrazines

2020
Combination treatment with CPX-351 and midostaurin in patients with secondary acute myeloid leukaemia that are FLT3 mutated: three cases and review of literature.
    British journal of haematology, 2020, Volume: 190, Issue:3

    Topics: Aged; Allografts; Anemia, Refractory, with Excess of Blasts; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Breast Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials, Phase III as Topic; Cytarabine; Daunorubicin; Fatal Outcome; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm, Residual; Neoplasms, Radiation-Induced; Oncogene Proteins, Fusion; Peripheral Blood Stem Cell Transplantation; Point Mutation; Protein Kinase Inhibitors; Pyrazines; Remission Induction; Salvage Therapy; Staurosporine; Sulfonamides

2020
Gilteritinib in Isolated Breast Relapse of FLT3 Positive Acute Myeloid Leukemia: A Case Report and Review of Literature.
    Acta haematologica, 2022, Volume: 145, Issue:5

    Topics: Aged; Aniline Compounds; Azacitidine; Cytarabine; Daunorubicin; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Pyrazines; Recurrence

2022

Trials

2 trial(s) available for pyrazines and daunorubicin

ArticleYear
Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Mar-01, Volume: 31, Issue:7

    Topics: Aged; Antigens, Differentiation, B-Lymphocyte; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Administration Schedule; Drug Synergism; Female; Follow-Up Studies; Histocompatibility Antigens Class II; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Peripheral Nervous System; Pyrazines; Remission Induction; Survival Analysis; Treatment Outcome

2013
Entospletinib in Combination with Induction Chemotherapy in Previously Untreated Acute Myeloid Leukemia: Response and Predictive Significance of
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 11-15, Volume: 26, Issue:22

    Topics: Adult; Cytarabine; Daunorubicin; Female; Gene Expression Regulation, Neoplastic; Homeodomain Proteins; Humans; Indazoles; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloid Ecotropic Viral Integration Site 1 Protein; Pyrazines; Syk Kinase

2020

Other Studies

10 other study(ies) available for pyrazines and daunorubicin

ArticleYear
Proteasome inhibitor-induced apoptosis in acute myeloid leukemia: a correlation with the proteasome status.
    Leukemia research, 2010, Volume: 34, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Daunorubicin; Drug Resistance, Neoplasm; Female; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Leupeptins; Male; Middle Aged; Prognosis; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Tumor Cells, Cultured; U937 Cells

2010
Combined effects of bortezomib and daunorubicin on multiple myeloma cell KM3 in vitro.
    Zhongguo shi yan xue ye xue za zhi, 2009, Volume: 17, Issue:6

    Topics: Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Daunorubicin; Drug Synergism; Humans; Inhibitory Concentration 50; Multiple Myeloma; Pyrazines

2009
[Effects of bortezomib combined with daunorubicin on proliferation and apoptosis in primary adult acute leukemia].
    Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2010, Volume: 41, Issue:5

    Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Daunorubicin; Drug Synergism; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines; Tumor Cells, Cultured; Young Adult

2010
[The anti-leukemic effects of imatinib, daunorubicin and bortezomib on two leukemia cell lines with Ph(+)].
    Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2010, Volume: 41, Issue:5

    Topics: Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; Cell Line, Tumor; Daunorubicin; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines; Pyrimidines

2010
Proteasome inhibitor bortezomib overcomes P-gp-mediated multidrug resistance in resistant leukemic cell lines.
    International journal of laboratory hematology, 2012, Volume: 34, Issue:3

    Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Daunorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; G2 Phase Cell Cycle Checkpoints; Humans; K562 Cells; Leukemia; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines

2012
[Treatment of acute myeloid leukemia -- a single center experience (2007-2013)].
    Orvosi hetilap, 2014, Apr-27, Volume: 155, Issue:17

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cytarabine; Daunorubicin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Hungary; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Palliative Care; Prognosis; Pyrazines; Retrospective Studies; Survival Analysis; Survival Rate; Transplantation, Homologous; Treatment Outcome; Vidarabine

2014
Molecular mechanisms of converting K562/DNR cellular drug-resistance by bortezomib.
    European review for medical and pharmacological sciences, 2014, Volume: 18, Issue:10

    Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Boronic Acids; Bortezomib; Daunorubicin; Drug Resistance, Neoplasm; Humans; I-kappa B Proteins; K562 Cells; NF-kappa B; Pyrazines

2014
How I treat acute myeloid leukemia in the era of new drugs.
    Blood, 2020, 01-09, Volume: 135, Issue:2

    Topics: Adult; Aged; Aminopyridines; Aniline Compounds; Antineoplastic Agents; Biomarkers, Tumor; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Female; fms-Like Tyrosine Kinase 3; Glycine; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Male; Molecular Targeted Therapy; Mutation; Prognosis; Pyrazines; Pyridines; Sialic Acid Binding Ig-like Lectin 3; Staurosporine; Sulfonamides; Triazines

2020
What to use to treat AML: the role of emerging therapies.
    Hematology. American Society of Hematology. Education Program, 2021, 12-10, Volume: 2021, Issue:1

    Topics: Aged; Aminopyridines; Aniline Compounds; Antineoplastic Agents; Cytarabine; Daunorubicin; Drug Approval; Drug Discovery; Glycine; Humans; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Pyrazines; Pyridines; Triazines

2021
Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML.
    Leukemia, 2022, Volume: 36, Issue:10

    Topics: Animals; Benzamides; Cell Line, Tumor; Daunorubicin; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Focal Adhesion Kinase 2; Humans; Leukemia, Myeloid, Acute; Mice; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proteome; Pyrazines; Sulfonamides

2022